Enveric reports differentiated brain activity for EB-003 in mice
The preclinical qEEG study shows central nervous system penetration and a neurophysiological profile distinct from DMT, supporting use as a biomarker.
Latest Enveric Biosciences News & Updates
See the latest news and media coverage for Enveric. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing drug candidates for mental health disorders
enveric.com- Headquarters
- Cambridge, United States
- Founded year
- 2020
- Company type
- Public company
- Number of employees
- 12–50
- Industry
- Pharmaceuticals
Last updated
Latest news about Enveric Biosciences (Enveric)
In short: Enveric reported positive EB-003 ADMET results supporting advancement toward a planned first-in-human trial.
Company announcements
Enveric reports positive IND-enabling ADMET results for EB-003
The studies show favorable oral absorption, systemic bioavailability and stability, and reduced drug-drug interaction risk, supporting advancement toward a planned first-in-human trial.
Enveric advances EB-003 through IND-enabling development
EB-003 targets 5-HT2A and 5-HT1B receptors to harness neuroplasticity pathways, aiming to treat difficult-to-treat neuropsychiatric disorders and reach first-in-human clinical studies.
Enveric reports second quarter 2026 financial results and progress
Net loss was $3.0 million with $8.3 million cash on hand; it raised $6.5 million and advanced EB-003 IND-enabling studies and patents.
Media coverage
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
"The second quarter was highlighted by important progress across the key activities supporting our planned first-in-human clinical trial of EB-003," said Joseph Tucker, Ph.D., Chief...
Enveric Biosciences Earnings Q3 2026 | ENVB News & Analysis
Regulatory roadmap: What specific preclinical or safety bottlenecks remain that could delay the targeted IND submission for EB-003 in the next 12 months? ... ENVB...
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...
Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading
Enveric Biosciences (ENVB, Financials) priced a $5 million public offering, sending its shares down...
Never miss news about Enveric
Track Enveric and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Enveric competitors & trending companies
Browse news for competitors to Enveric and other trending companies.
Sensorium
Sobrera
Saniona
NRx
Reunion
JAPEX
M&P
Predator
Perenco
Dana Petroleum
Harbour
Chariot
Horizon
TransAtlantic Petroleum
DO
Hokchi Energy
Dubai Petroleum
CalEnergy
Canadian Natural
CEP
ABIR
RG
Curis
MPLX
Mosaic
Fortitude Re
Brit
Convex
Sompo
Somers Group
Pelagos
Vantage
Premia
Mereo
Longtail Re
Assured Guaranty